China guideline for pharmaceutical care on anti-tumor antibody-based drugs.
10.3760/cma.j.cn112152-20220902-00593
- Collective Name:National Cancer Center;Cancer Pharmacists Branch of Chinese Pharmacists Association
- Publication Type:Journal Article
- Keywords:
Anti-tumor antibody drugs;
Guideline;
Malignant tumor;
Pharmaceutical services
- MeSH:
Humans;
Pharmaceutical Preparations;
Pharmaceutical Services;
Pharmacists;
Antineoplastic Agents;
Antibodies, Monoclonal;
China
- From:
Chinese Journal of Oncology
2022;44(10):1017-1046
- CountryChina
- Language:Chinese
-
Abstract:
Antibody-based drugs are prepared by cell and genetic engineering technology, which are widely used in the treatment of malignant tumors. According to the structural characteristics, antibody-based drugs currently on the market can be divided into several categories, including monoclonal antibody drugs, bispecific antibody drugs and antibody drug conjugates. Until June 1, 2022, 39 anti-tumor antibody drugs have been approved in China. Since the pharmaceutical characteristics, in vivo efficacy and pharmacokinetic characteristics of anti-tumor antibody drugs are different from those of traditional small molecule drugs, the pharmaceutical care of anti-tumor antibody drugs in clinical application has distinct features. To regulate pharmaceutical care of these drugs, promote the rational use of antibody drugs in China, this guideline has been made by Cancer Pharmacists Branch of Chinese Pharmacists Association, with the guidance of the National Cancer Center. We used the Delphi method and expert interview and discussion, to build the key problems. The contents in this guideline are based on clinical evidence, domestic pharmaceutical management regulations and pharmaceutical care practice. This guideline covers the whole process of pharmaceutical care system, includes the using of before, during and after drug administration. It provides a scientific basis for pharmacists to carry out pharmaceutical care for this kind of drugs.
